7. Effects of angiotensin converting enzyme inhibitors (ACEi) versus other classes of antihypertensive medication.

Outcome	Trial identifier	Comparator class	RR (95% CI)
Incidence of DR	DEMAND	ACEi + CCB	0.48 (0.13, 1.86)
Progression of DR	UKPDS/HDS	Beta blocker	1.01 (0.75, 1.35)
Combined incidence and progression of DR	ABCD (1)	CCB	1.33 (0.93, 1.92)
	ABCD (2)	CCB	0.93 (0.71, 1.21)
	RASS	ARB	0.89 (0.49, 1.87
Regression of DR	BENEDICT	Non‐ACEi	0.44 (0.22, 0.87)
All‐cause mortality	UKPDS/HDS	Beta blocker	0.88 (0.64, 1.20)

ACEi, angiotensin‐converting enzyme inhibitor
ARB, angiotensin receptor blocker
CCB, calcium channel blocker
DR, diabetic retinopathy
RR, risk ratio
CI, confidence interval